Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$11.13M$11.13M−9.3% vs Q1 2022 Net Income$8.07M$8.07MN/M vs Q1 2022 EPS Diluted$0.11$0.11N/M vs Q1 2022 Operating Income-$4,605,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Free Cash Flowderived$8,814,000N/M Margins · derivedOperating margin-41.4%+38.0 pt vs Q1 2022
Net margin72.5%+180.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 2, 2023 · 32 d after period end